Laval, Canada-based Valeant Pharmaceuticals will hold onto its gastrointestinal division, Salix, after talks fell apart with Japan's Takeda Pharmaceuticals, Bloomberg reports.
GI & Endoscopy
Scott D. Becker, MD, is a gastroenterologist and the director of clinical research at Austin (Texas) Gastroenterology.
Here are three gastroenterologists in the news this past week.
Despite falling revenues, Madison, N.J.-based Allergan's gastroenterology franchise grew by 8.2 percent in the third quarter, Market Realist reports.
Cambridge, Mass.-based Idera Pharmaceuticals and Bermuda-based Vivelix Pharmaceuticals entered into an exclusive license and collaboration agreement giving Vivelix the rights to develop and market IMO-9200, an antagonist of TLR 7,8 and 9, for non-malignant gastrointestinal disorders.
Advertisement
Michael Gilbert Goggins, MD, is a gastroenterologist and a professor of pathology, medicine and oncology at Baltimore's John Hopkins Medicine.
Genetic Technologies and Australia-based University of Melbourne have entered a license agreement to develop a new colorectal cancer risk assessment test.
A study in the American Journal of Gastroenterology investigated whether offering small financial incentives to patients increases colorectal cancer screening compliance.
Carl Gessner, MD, is a gastroenterologist at Greensboro, N.C.-based LeBauer HealthCare.
Future Market Insights believes the video endoscopy market is poised for growth, according to a new report.